生物学引导放疗在肺癌中的可行性、工作流程、剂量学及PET信号趋势
该研究首次报告了RefleXion X1平台生物学引导放疗(BgRT)在27例肺肿瘤患者中的临床应用,其中14例接受立体定向放疗(≤5次)。12例完成全部BgRT分次,2例因PET信号不足和机器联锁转为常规图像引导放疗。BgRT计划满足机构剂量学标准,中位束流时间29分钟,中位总操作时间116分钟。
要点
- BgRT在肺癌患者中临床可行,多数患者完成全部计划分次。
- PET信号在多数患者中稳定,活度浓度和归一化靶区信号逐渐下降但仍在临床可接受阈值内。
- 中位束流时间29分钟,中位总操作时间116分钟,支持临床可行性。
核心结论
- RefleXion X1系统的BgRT在肺癌患者中临床可行,在可评估分次中显示短期耐受性初步指标。
研究设计与样本
- 连续队列研究,纳入2023年12月至2025年1月期间27例肺肿瘤患者评估BgRT,其中14例接受≤5次立体定向放疗。
主要发现
- 14例接受BgRT的患者中12例完成全部计划分次,2例分别因PET信号不足和机器联锁转为常规图像引导放疗。
- 多数患者FDG亲和力稳定,活度浓度和归一化靶区信号逐渐下降但仍在临床可接受阈值内。
- 中位计划靶区V100%为95.6%(范围72.2%-97.7%),中位束流时间29分钟(范围10-48分钟),中位总操作时间116分钟(范围91-136分钟)。
关键数值与推荐
- BgRT计划满足机构剂量学标准,中位计划靶区V100%为95.6%(范围72.2%-97.7%),并实现适当的危及器官保护。
临床怎么用
- BgRT可整合入常规实践,但需注意PET信号不足可能导致治疗转换,并需关注操作时间。
局限性
- 样本量小(14例接受BgRT),为单中心首次临床经验,需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Biology guided radiation therapy (BgRT), a novel treatment approach, integrates real-time positron emission tomography (PET) imaging with external beam delivery to enable tumor-targeted dose modulation. Lung tumors, given their high ¹⁸F-fluorodeoxyglucose (FDG) uptake and low background activity, are considered ideal candidates for BgRT. This study presents the first clinical experience of BgRT in lung cancer, evaluating treatment workflow, plan quality, PET signal characteristics, and delivery timing. METHODS AND MATERIALS: A consecutive cohort of 27 patients with lung tumors was evaluated for BgRT using the RefleXion X1 platform between December 2023 and January 2025. Of these, 14 patients received stereotactic body radiation therapy in 5 or fewer fractions. PET modeling and pretreatment PET evaluation were performed to assess activity concentration and normalized target signal. Key metrics included treatment completion rate, plan quality parameters, temporal trends in FDG signal across fractions, and a timing analysis of treatment delivery encompassing imaging, planning, and delivery workflows. RESULTS: Among the 14 patients treated with BgRT, 12 completed all planned BgRT fractions. Two were transitioned to conventional image guided radiation therapy due to insufficient PET signal and machine interlock, respectively. PET-based metrics demonstrated stable FDG avidity in most patients with gradual declines in activity concentration and normalized target signal that remained within clinically acceptable thresholds. BgRT plans met institutional dosimetric criteria, achieving a median planning target volume V100% = 95.6% (range, 72.2%-97.7%) and appropriate organ sparing. The median beam-on time was 29 minutes (range, 10-48 minutes), and the median total procedure time was 116 min (range, 91-136 min), supporting clinical feasibility. CONCLUSIONS: BgRT using the RefleXion X1 system is clinically feasible, with preliminary indicators of short-term tolerability among evaluable fractions in lung cancer patients. This initial experience demonstrates reliable PET signal acquisition, consistent plan quality, and efficient delivery. These findings support the potential integration of BgRT into routine practice and justify further prospective studies in other disease sites.
引用
- Lin CS, Shen C, Banks T, et al. Feasibility, Workflow, Dosimetry, and Positron Emission Tomography Signal Trends in Lung Cancer Treated With Biology-Guided Radiation Therapy. Int J Radiat Oncol Biol Phys. 2026. PMID: 41651387. doi:10.1016/j.ijrobp.2025.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。